These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 10496361

  • 21. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A.
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK.
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [Abstract] [Full Text] [Related]

  • 23. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.
    Clin Cancer Res; 2005 Jul 01; 11(13):4843-50. PubMed ID: 16000582
    [Abstract] [Full Text] [Related]

  • 24. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Br J Clin Pharmacol; 2005 Mar 01; 59(3):325-34. PubMed ID: 15752379
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of two types of population pharmacokinetic model structures of paclitaxel.
    Fransson M, Gréen H.
    Eur J Pharm Sci; 2008 Feb 05; 33(2):128-37. PubMed ID: 18083353
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
    Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M.
    Br J Clin Pharmacol; 2002 May 05; 53(5):508-18. PubMed ID: 11994057
    [Abstract] [Full Text] [Related]

  • 28. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A.
    J Clin Oncol; 2002 Jan 15; 20(2):574-81. PubMed ID: 11786588
    [Abstract] [Full Text] [Related]

  • 29. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G, Bartoli Klugmann F, Candussio L, Baldini L.
    Anticancer Res; 1996 Jan 15; 16(1):317-20. PubMed ID: 8615628
    [Abstract] [Full Text] [Related]

  • 30. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A.
    Anticancer Drugs; 2000 Jun 15; 11(5):331-7. PubMed ID: 10912949
    [Abstract] [Full Text] [Related]

  • 31. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
    Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD.
    Clin Cancer Res; 2003 Jan 15; 9(1):151-9. PubMed ID: 12538463
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
    Briasoulis E, Karavasilis V, Tzamakou E, Haidou C, Piperidou C, Pavlidis N.
    Anticancer Drugs; 2002 Jun 15; 13(5):481-9. PubMed ID: 12045459
    [Abstract] [Full Text] [Related]

  • 33. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
    Stage TB, Bergmann TK, Kroetz DL.
    Clin Pharmacokinet; 2018 Jan 15; 57(1):7-19. PubMed ID: 28612269
    [Abstract] [Full Text] [Related]

  • 34. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ.
    Clin Cancer Res; 2004 Jun 01; 10(11):3708-16. PubMed ID: 15173077
    [Abstract] [Full Text] [Related]

  • 35. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL, Kossoff E.
    Pharmacotherapy; 2009 Aug 01; 29(8):993-6. PubMed ID: 19637953
    [Abstract] [Full Text] [Related]

  • 36. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
    Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I.
    Eur J Pharm Biopharm; 2005 Jan 01; 59(1):177-87. PubMed ID: 15567316
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):105-11. PubMed ID: 16699792
    [Abstract] [Full Text] [Related]

  • 38. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment.
    Knemeyer I, Wientjes MG, Au JL.
    Cancer Chemother Pharmacol; 1999 Jan 01; 44(3):241-8. PubMed ID: 10453726
    [Abstract] [Full Text] [Related]

  • 39. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal.
    Kessel D, Woodburn K, Decker D, Sykes E.
    Oncol Res; 1995 Jan 01; 7(5):207-12. PubMed ID: 8534926
    [Abstract] [Full Text] [Related]

  • 40. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K, Jin M, Furui N, Yamazaki M, Yoshihara H, Nomura M, Furukawa H, Ishizaki J, Fushida S, Miwa K, Miyamoto K.
    J Pharm Pharmacol; 2004 May 01; 56(5):629-34. PubMed ID: 15142340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.